[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Advisory Board
Aims & Scope
Journal News
Articles archive::
All Issues
Current Issue
Articles in press
For Authors::
Submission Instruction
For Reviewers::
Reviewers Section
Subscription::
Subscription Form
News& Events::
Journal News
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
Top 10 contents
Inform others
Ethics & Permissions::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 19, Issue 3 (Autumn 2022) ::
Sci J Iran Blood Transfus Organ 2022, 19(3): 243-255 Back to browse issues page
Management of stem cell transplantation with major ABO blood group incompatibility: Pure Red cell aplasia
M. Soleimani , F. Tavakoli , M. Ghadyani , M. Mohammadian Rastani , M. Tabarraee , E. Roshandel
Keywords: Hematopoietic Stem Cell Transplantation, ABO Blood-Group System, Pure Red-Cell Aplasia
Full-Text [PDF 551 kb]   (505 Downloads)     |   Abstract (HTML)  (603 Views)
Type of Study: Review Article | Subject: Hematology
Published: 2022/10/2
Full-Text:   (538 Views)
References:
  1. Mardani M, Abolghasemi S, Shabani S, Tavakoli F, Saeedi A, Parkhideh S, et al. The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Iran J Microbiol 2020; 12: 636-43.
  2. Anbarlou A, Rahnama MA, Atashi A, Soleimani M. Selective serotonin reuptake inhibitors may improve the efficacy of hematopoietic stem cells transplantation. Journal of Exploratory Research in Pharmacology 2016; 1(1): 16-9.
  3. Saba F, Soleimani M, Atashi A, Mortaz E, Shahjahani M, Roshandel E, et al. The role of the nervous system in hematopoietic stem cell mobilization. Lab Hematol 2013; 19(3): 8-16.
  4. Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfus Med Hemother 2016; 43(1): 3-12.
  5. Damodar S, George B, Mammen J, Mathews V, Srivastava A, Chandy M. Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants. Bone Marrow Transplant 2005; 36(3): 233-5.
  6. Méndez GA, Arroyo JL, Amunárriz C, Romón Í. ABO-mismatched marrow processing for transplantation: Comparative results of 80 procedures performed with Cobe Spectra and Spectra Optia. Transfus Apher Sci 2019; 58(3): 326-31.
  7. Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol 2016; 9(1): 1-12.
  8. Shokrgozar N, Tamaddon G. ABO blood grouping mismatch in hematopoietic stem cell transplantation and clinical guides. Int J Hematol Oncol Stem Cell Res 2018; 12(4): 322.
  9. Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19(8): 1152-8.
  10. Yahng SA, Lee JW, Kim Y, Kim M, Oh EJ, Park YJ, et al. New proposed guidelines for early identification of successful myeloid and erythroid engraftment in hematopoietic stem cell transplantation. J Clin Lab Anal 2014; 28(6): 469-77.
  11. Marco-Ayala J, Gómez-Seguí I, Sanz G, Solves P. Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question. Bone Marrow Transplant 2021; 56(4):769-78.
  12. Tomac G, Bojanić I, Mazić S, Vidović I, Raos M, Ćepulić BG, et al. Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation. Blood Transfus 2018; 16(4): 397.
  13. Jeyaraman P, Borah P, Rajput P, Dayal N, Pathak S, Naithani R. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. Blood Cells Mol Dis 2021; 88: 102464.
  14. OmidKhoda A, Gharehbaghian A, Jamali M, AhmadBeigi N, Hashemi SM, Rahimi A, et al. Comparison of the prevalence of major transfusion-transmitted infections among Iranian blood donors using confidential unit exclusion in an Iranian population: Transfusion-transmitted infections among Iranian blood donors. Hep Mon 2011; 11(1): 11.
  15. Parkhideh S, Chegeni R, Mehdizadeh M, Roshandel E, Tavakoli F, Hajifathali A. Effects of ABO incompatibility on the outcome of allogeneic hematopoietic stem cell transplantation. Transfus Aphe Sci 2020; 59(2): 102696.
  16. Soares JA, Martinho GH, Macedo AVd, Verçosa MR, Nobre V, Teixeira GM. Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study. Hematol Transfus Cell Ther 2019; 41: 1-6.
  17. Damodar S, Shanley R, MacMillan M, Ustun C, Weisdorf D. Donor-to-recipient ABO mismatch does not impact outcomes of allogeneic hematopoietic cell transplantation regardless of graft source. Biology of Blood  and  Marrow Transplantation 2017; 23(5): 795-804.
  18. Atilla PA, Akkus E, Atilla E, Gokmen N, Bozdag SC, Toprak SK, et al. Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Transfus Clin Biol 2020; 27(3): 115-21.
  19. Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, et al. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21(4): 746-54.
  20. Hefazi M, Litzow M, Hogan W, Gastineau D, Jacob E, Damlaj M, et al. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. Transfusion 2016; 56(2): 518-27.
  21. Rauofi A, Hajifathali A, Karami S, Tavakoli F, Roshandel E, Bonakchi H, et al. The apheresis content analysis in Allo-HSCT represents reliable influential factors on graft-versus-host disease and overall survival. Transfus Apher Sci 2021; 60(2): 103009.
  22. Sheppard D, Tay J, Bryant A, McDiarmid S, Huebsch L, Tokessy M, et al. Major ABO-incompatible BMT: isohemagglutinin reduction with plasma exchange is safe and avoids graft manipulation. Bone Marrow Transplant 2013; 48(7): 953-7.
  23. Brauninger S, Bialleck H, Thorausch K, Felt T, Seifried E, Bonig H. Allogeneic donor peripheral blood “stem cell” apheresis: prospective comparison of two apheresis systems. Transfusion 2012; 52(5): 1137-45.
  24. Akel S, Murray C, Ferguson W, Babic A. Outcomes of processing of bone marrow harvests for hematopoietic stem cell transplantation in pediatric patients utilizing a novel red blood cell sedimentation kit. Transfusion 2019; 59(7): 2375-81.
  25. Stussi G, Halter J, Bucheli E, Valli PV, Seebach L, Gmür J, et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica 2009; 94(2): 239.
  26. Longval T, Galimard JE, Leprêtre AC, Suarez F, Amiranoff D, Cazaux M, et al. Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol 2021; 193(4): 814-26.
  27. De Santis GC, Garcia-Silva AC, Dotoli GM, de Castro PT, Simões BP, Covas DT. Higher Anti-A/B isoagglutinin titers of IgG class, but not of IgM, are associated with increased red blood cell transfusion requirements in bone marrow transplantation with major ABO-mismatch. Clin Transplant 2017; 31(4): e12913.
  28. Choi SJ, Kim HS, Kim Y, Lee JW, Lim J. Efficacy of three consecutive therapeutic plasma exchanges in major ABO-incompatible hematopoietic stem cell transplantation. J Clin Apher 2019; 34(4): 367-72.
  29. Scholl S, Klink A, Mügge LO, Schilling K, Höffken K, Sayer HG. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Transfusion 2005; 45(10): 1676-83.
  30. Busca A, Dellacasa C, Giaccone L, Manetta S, Biale L, Godio L, et al. Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2018; 24(8): 1765-70.
  31. Helbig G, Stella-Holowiecka B, Wojnar J, Krawczyk M, Krzemien S, Wojciechowska-Sadus M, et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Ann Hematol 2007; 86(9): 677-83.
  32. Won DI, Ham JY, Kim CD, Suh JS, Kim BC. Benefits of fresh-frozen plasma as a replacement fluid to neutralize ABO antibodies. J Clin Apher 2015; 30(5): 288-96.
  33. Quek J, Lee JJ, Lim FL, Diong C, Goh YT, Gopalakrishnan S, et al. Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. Transfusion 2019; 59(1): 335-9.
  34. Rabitsch W, Knöbl P, Greinix H, Prinz E, Kalhs P, Hörl WH, et al. Removal of persisting isohaemagglutinins with Ig-Therasorb® immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation. Nephrol Dial Transplant 2003; 18(11): 2405-8.
  35. Yanagisawa R, Nakazawa H, Nishina S, Saito S, Shigemura T, Tanaka M, et al. Investigation of risk factors associated with erythrocyte engraftment after ABO-incompatible hematopoietic stem cell transplantation. Clin Transplant 2021; 35(6): e14300.
  36. Verholen F, Stalder M, Helg C, Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 2004; 73(6): 441-6.
  37. Handisurya A, Worel N, Rabitsch W, Bojic M, Pajenda S, Reindl-Schwaighofer R, et al. Antigen-specific immunoadsorption with the Glycosorb® ABO immunoadsorption system as a novel treatment modality in pure red cell aplasia following major and bidirectional ABO-incompatible allogeneic hematopoietic stem  cell  transplantation.  Front Med 2020; 7: 693.
  38. Crysandt M, Soysal H, Jennes E, Holtick U, Mrotzek M, Rehnelt S, et al. Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility. Eur J Haematol 2021; 107(3): 324-32.
  39. Perricone C, Triggianese P, Bursi R, Cafaro G, Bartoloni E, Chimenti MS, et al. Intravenous immunoglobulins at the crossroad of autoimmunity and viral infections. Microorganisms 2021; 9(1): 121.
  40. Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013; 56(7): 968-77.
  41. Isoda A, Miyazawa Y, Tahara K, Mihara M, Saito A, Matsumoto M, et al. Pembrolizumab-induced pure red cell aplasia successfully treated with intravenous immunoglobulin. Int Med 2020; 59(16): 2041-5.
  42. Paltiel O, Cournoyer D, Rybka W. Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion 1993; 33(5): 418-21.
  43. Roychowdhury D, Linker C. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant 1995;16(3): 471-2.
  44. Ohashi K, Akiyama H, Takamoto S, Tanikawa S, Sakamaki H, Onozawa Y. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team. Bone Marrow Transplant 1994; 13(3): 335-6.
  45. Gupta R, Ezeonyeji A, Thomas A, Scully M, Ehrenstein M, Isenberg D. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: Responseto rituximab and cyclophosphamide. Lupus 2011; 20(14): 1547-50.
  46. Abongwa C, Abusin G, El-Sheikh A. Successful treatment of tacrolimus-related pure red cell aplasia and autoimmune hemolytic anemia with rituximab in a pediatric cardiac transplant patient. Pediatr Blood Cancer 2017; 64(12): e26674.
  47. Kopińska A, Helbig G, Frankiewicz A, Grygoruk-Wiśniowska I, Kyrcz-Krzemień S. Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation. Contemp Oncol 2012; 16(3): 215.
  48. Griffith L, McCoy Jr J, Bolan C, Stroncek D, Pickett A, Linton G, et al. Persistence of recipient plasma cells and anti‐donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 2005; 128(5): 668-75.
  49. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 2013; 160(6): 798-805.
  50. Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, et al. Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation: may we predict graft-versus-leukemia without graft-versus-host disease? Biol  Blood  Marrow  Transplant  2015; 21(7): 1230-6.
  51. Musso M, Porretto F, Crescimanno A, Polizzi V, Scalone R. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 2004; 33(7): 769-71.
  52. Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med 2018; 379(19): 1846-50.
  53. Poon L, Koh L. Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib. Bone Marrow Transplant 2012; 47(6): 870-1.
  54. Sackett K, Cohn CS, Fahey-Ahrndt K, Smith AR, Johnson AD. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apher 2018; 33(1): 108-12.
  55. Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol 2019; 94(8): E216-E9.
  56. Khan F, Linden MA, Zantek ND, Vercellotti GM. Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation. Transfus Med 2014; 24(3): 187.
  57. Shahan J, Hildebrandt G. Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma. Transfus Med 2015; 25(5): 342-4.
  58. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 2019; 6(3): e132-e43.
  59. Caballero-Velázquez T, Calderón-Cabrera C, López-Corral L, Puig N, Marquez-Malaver F, Pérez-López E, et al. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplant 2020; 55(2): 419-30.
  60. Nakane T, Okamura H, Tagaito Y, Koh S, Yoshimura T, Makuuchi Y, et al. Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients. Int J Hematol 2019; 110(6): 736-42.
  61. Rautenberg  C,   Kaivers   J,   Germing   U,   Haas    R, Ackerstaff S, Hoffmann T, et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. Bone Marrow Transplant 2020; 55(6): 1191-3.
  62. Salas MQ, Alahmari A, Lipton JH. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol 2020; 104(2): 145-7.
  63. Yates B, Molloy E, Dulau-Florea A, Braylan R, Hogan L, Hickstein DD, et al. Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation. Transfusion 2021; 61(4): 1041-6.
  64. Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm 2021; 29(7-8): 1585-90. 
  65. Basu S, Dhar S, Mishra D, Chandy M. Clinico-serologic co-relation in bi-directional ABO incompatible hemopoietic stem cell transplantation. Asian J Transfus Sci 2015; 9(2): 181-4.
  66. Nakamura N, Ninomiya S, Matsumoto T, Nakamura H, Kitagawa J, Hara T, et al. Recovery of Pure Red Cell Aplasia Following Hematopoietic Stem Cell Transplantation Associated with IL-6 Elevation Caused by Odontogenic Infection. Int Med 2018: 0869-18.






Sci J Iran Blood Transfus Organ 2022;19 (3): 243-255
Review Article
 


Management of stem cell transplantation with major ABO blood group incompatibility: Pure Red cell aplasia

Soleimani M.1, Tavakoli F.1, Ghadyani M.2, Mohammadian Rastani M.1, Tabarraee M.2,
Roshandel E.1



1Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran


Abstract
Background and Objectives
ABO-incompatible allo-HSCT leads to complications like pure red cell aplasia (PRCA), which involves 7-16% of ABO-incompatible recipients. In this condition, albeit the development of other hematopoietic lineages in the bone marrow engraftment is successful, erythroid precursors are missing; thus, patients may require blood transfusions because of severe anemia. An extensive variety of treatment strategies has been introduced for treating PRCA patients. This study reviewed the various PRCA treatments following allo-HSCT.

Materials and Methods
In this Review study, keywords including Pure Red-Cell Aplasia, Hematopoietic Stem Cell Transplantation, and ABO Blood-Group System were searched in PubMed and Google Scholar databases. Sixty-four articles were reviewed, and related data were extracted.

Results
There are three main approaches for treating PRCA: erythropoiesis with erythropoietin, reducing isoagglutinin levels, and immunomodulatory therapies/graft versus plasma cell effect.

Conclusions 
Monoclonal antibody drugs targeting plasma cells have shown unprecedented results. Overall, PRCA management ways incorporate: individual patients’ evaluation in order to select the proper treatment management for each case, a thorough monitoring approach from the first day of hospitalization, and predicting the possibility of PRCA as indicated by blood group antibodies’ levels.

Key words: Hematopoietic Stem Cell Transplantation, ABO Blood-Group System, Pure Red-Cell Aplasia





Received: 28 Feb 2022
Accepted: 23 Jul  2022



Correspondence: Roshandel E., PhD of Hematology & Blood Banking. Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences.
P.O.Box: 11151-19857, Tehran, Iran. Tel: (+9821) 23031657; Fax: (+9821) 22432570
E-mail: elham.roshandel@gmail.com

 
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soleimani M, Tavakoli F, Ghadyani M, Mohammadian Rastani M, Tabarraee M, Roshandel E. Management of stem cell transplantation with major ABO blood group incompatibility: Pure Red cell aplasia. Sci J Iran Blood Transfus Organ 2022; 19 (3) :243-255
URL: http://bloodjournal.ir/article-1-1443-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 3 (Autumn 2022) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.05 seconds with 37 queries by YEKTAWEB 4645